Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
Abstract Background Triple negative breast cancer (TNBC) remains the most challenging breast cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical improvements in treatment of TNBC patients and effective molecular biomarkers are largely unknown. Methods We used paired...
Main Authors: | Jie Li, Maoguang Ma, Xuesong Yang, Maolei Zhang, Jingyan Luo, Huangkai Zhou, Nunu Huang, Feizhe Xiao, Bingquan Lai, Weiming Lv, Nu Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-020-01259-6 |
Similar Items
-
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
by: Jie Li, et al.
Published: (2021-10-01) -
Circular RNA Expression Profiling by Microarray—A Technical and Practical Perspective
by: Yanggu Shi, et al.
Published: (2023-04-01) -
Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01) -
circRNA_0001006 predicts prognosis and regulates cellular processes of triple-negative breast cancer via miR-424-5p
by: Jiaqi Liu, et al.
Published: (2023-05-01) -
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR
by: Xiaolong Wang, et al.
Published: (2022-08-01)